Relationship Between Liver Cancer and Sarcopenia

Sarcopenia Clinical Trial

Official title:

The Effect of Sarcopenia on Hepatocellular Carcinoma After Hepatectomy

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05339919
• Other study ID #: sarcopenia
• Status: Enrolling by invitation
• Start date: May 1, 2020
• Est. completion date: August 28, 2025

Study information

• Verified date: June 2022
• Source: First Affiliated Hospital of Wenzhou Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

By tracking the short-term and long-term results of patients after hepatectomy, the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after hepatectomy was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.

Description:

All implementation details are based on the newest EWGSOP definition. The investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (L3 plane total skeletal muscle area) and physical performance (gait test) following the F-A-C-S approach, to confirm patients with sarcopenia accurately. And by tracking the short-term and long-term outcomes of patients after hepatectomy, the differences were analyzed and the relationship between sarcopenia and liver cancer was explored.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 1200
• Est. completion date: August 28, 2025
• Est. primary completion date: August 11, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with preoperative clinical diagnosis of liver cancer
• No cancer other than liver cancer has been diagnosed
• Age =18 years

Exclusion Criteria:

• Patients who could not complete the standard tests and questionnaires
• Patients who did not accept liver resection after evaluation of treatment plan
• Patients who had other concomitant preoperative causes of muscle weakness (injury, fracture, stroke, etc.)
• Patients who missing CT data or CT scan did not reach the level of the third lumbar vertebra (L3)

Related Conditions & MeSH terms

• Liver Cancer
• Liver Neoplasms
• Sarcopenia

Intervention

Diagnostic Test:
• gait speed; ct scan;grip strength and chair stand test
The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.

Locations

Country	Name	City	State
China	Gang Chen	Wenzhou	Zhejiang

Sponsors (3)

Lead Sponsor	Collaborator
First Affiliated Hospital of Wenzhou Medical University	Qilu Hospital of Shandong University, The Second Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Short-term postoperative results	Postoperative complications;90 days readmission rate	3 months
Primary	Long-term results after operation	Overall survival; Disease free survival	10 years
Secondary	Postoperative hospitalization time	Time window from the day of operation to the day of discharge.	2 months
Secondary	Hospitalization expenses	All hospitalization expenses, including drug expenses, operation expenses, anesthesia expenses, nursing expenses and other expenses.	2 months